Mesirow Financial Investment Management Inc. Sells 1,901 Shares of Amgen Inc. $AMGN

Mesirow Financial Investment Management Inc. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 12.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,137 shares of the medical research company’s stock after selling 1,901 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Amgen were worth $4,300,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in AMGN. Pinnacle Associates Ltd. boosted its holdings in shares of Amgen by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 63,117 shares of the medical research company’s stock valued at $20,659,000 after acquiring an additional 434 shares in the last quarter. Financial Council LLC acquired a new position in Amgen in the 4th quarter worth about $227,000. Simmons Bank raised its position in Amgen by 7.1% in the fourth quarter. Simmons Bank now owns 24,108 shares of the medical research company’s stock valued at $7,891,000 after purchasing an additional 1,602 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Amgen by 300.2% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,757 shares of the medical research company’s stock valued at $606,000 after purchasing an additional 1,318 shares in the last quarter. Finally, Western Wealth Management LLC boosted its stake in shares of Amgen by 3.2% during the fourth quarter. Western Wealth Management LLC now owns 4,297 shares of the medical research company’s stock valued at $1,407,000 after purchasing an additional 133 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the subject of several recent research reports. Daiwa Securities Group lowered their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday. Erste Group Bank reissued a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. The Goldman Sachs Group raised their price target on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research note on Friday, May 1st. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Piper Sandler reduced their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating on the stock in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus price target of $356.15.

Amgen Stock Performance

NASDAQ:AMGN opened at $336.23 on Friday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $264.15 and a fifty-two week high of $391.29. The company has a 50 day simple moving average of $350.23 and a two-hundred day simple moving average of $343.11. The company has a market capitalization of $181.46 billion, a PE ratio of 23.40, a P/E/G ratio of 3.38 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the company earned $4.90 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts anticipate that Amgen Inc. will post 22.36 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen’s dividend payout ratio is 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.